Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)
Close on Nov 13, 2026Market cap $81.19MP/E –Yield –
Coherus Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Coherus Oncology's operating margin for the twelve months ending Sep 30, 2026 was -275.9%. For fiscal 2025 it was -429.5%, against -756.6% the year before. The highest annual figure on record is 32.9% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -429.5% | +327.1 |
| FY2024 | Dec 31, 2024 | -756.6% | −677.6 |
| FY2023 | Dec 31, 2023 | -79.0% | +42.7 |
| FY2022 | Dec 31, 2022 | -121.7% | −40.9 |
| FY2021 | Dec 31, 2021 | -80.8% | −113.7 |
| FY2020 | Dec 31, 2020 | 32.9% | +2.6 |
| FY2019 | Dec 31, 2019 | 30.3% | +14949.0 |
| FY2017 | Dec 31, 2017 | -14918.8% | −14857.8 |
| FY2016 | Dec 31, 2016 | -61.0% | +668.2 |
| FY2015 | Dec 31, 2015 | -729.2% | −521.3 |
| FY2014 | Dec 31, 2014 | -207.9% | +1100.4 |
| FY2013 | Dec 31, 2013 | -1308.4% | +720.0 |
| FY2012 | Dec 31, 2012 | -2028.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -235.7% | +147.4 |
| Q2 FY2026 | Jun 30, 2026 | -226.0% | +217.6 |
| Q1 FY2026 | Mar 31, 2026 | -293.7% | +304.2 |
| Q4 FY2025 | Dec 31, 2025 | -359.9% | +227.0 |
| Q3 FY2025 | Sep 30, 2025 | -383.1% | +391.1 |
| Q2 FY2025 | Jun 30, 2025 | -443.6% | −58.7 |
| Q1 FY2025 | Mar 31, 2025 | -597.9% | +2339.1 |
| Q4 FY2024 | Dec 31, 2024 | -586.9% | −511.6 |
| Q3 FY2024 | Sep 30, 2024 | -774.2% | −731.3 |
| Q2 FY2024 | Jun 30, 2024 | -384.9% | −326.0 |
| Q1 FY2024 | Mar 31, 2024 | -2937.0% | −2728.2 |
| Q4 FY2023 | Dec 31, 2023 | -75.3% | +38.3 |
| Q3 FY2023 | Sep 30, 2023 | -42.9% | +134.2 |
| Q2 FY2023 | Jun 30, 2023 | -58.8% | +14.3 |
| Q1 FY2023 | Mar 31, 2023 | -208.9% | −74.2 |
| Q4 FY2022 | Dec 31, 2022 | -113.5% | −59.6 |
| Q3 FY2022 | Sep 30, 2022 | -177.1% | −137.4 |
| Q2 FY2022 | Jun 30, 2022 | -73.2% | −45.6 |
| Q1 FY2022 | Mar 31, 2022 | -134.6% | +66.9 |
| Q4 FY2021 | Dec 31, 2021 | -53.9% | −68.8 |
| Q3 FY2021 | Sep 30, 2021 | -39.7% | −69.4 |
| Q2 FY2021 | Jun 30, 2021 | -27.6% | −75.7 |
| Q1 FY2021 | Mar 31, 2021 | -201.6% | −236.7 |
| Q4 FY2020 | Dec 31, 2020 | 14.9% | −21.5 |
| Q3 FY2020 | Sep 30, 2020 | 29.7% | −16.7 |
| Q2 FY2020 | Jun 30, 2020 | 48.1% | +15.2 |
| Q1 FY2020 | Mar 31, 2020 | 35.2% | +79.9 |
| Q4 FY2019 | Dec 31, 2019 | 36.4% | +4096.4 |
| Q3 FY2019 | Sep 30, 2019 | 46.4% | +45025.9 |
| Q2 FY2019 | Jun 30, 2019 | 33.0% | +8736.7 |
| Q1 FY2019 | Mar 31, 2019 | -44.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -4060.1% | – |
| Q1 FY2017 | Mar 31, 2017 | -44979.5% | – |
| Q4 FY2016 | Dec 31, 2016 | -8703.8% | – |
See a number that looks wrong?